RU2012107535A - КОМБИНАЦИЯ ХИМИОТЕРАПЕВТИЧЕСКОГО СРЕДСТВА И ИНГИБИТОРА СИСТЕМЫ TGF-β - Google Patents
КОМБИНАЦИЯ ХИМИОТЕРАПЕВТИЧЕСКОГО СРЕДСТВА И ИНГИБИТОРА СИСТЕМЫ TGF-β Download PDFInfo
- Publication number
- RU2012107535A RU2012107535A RU2012107535/15A RU2012107535A RU2012107535A RU 2012107535 A RU2012107535 A RU 2012107535A RU 2012107535/15 A RU2012107535/15 A RU 2012107535/15A RU 2012107535 A RU2012107535 A RU 2012107535A RU 2012107535 A RU2012107535 A RU 2012107535A
- Authority
- RU
- Russia
- Prior art keywords
- antisense oligonucleotide
- carcinoma
- tgf
- pharmaceutical composition
- composition according
- Prior art date
Links
- 102000004887 Transforming Growth Factor beta Human genes 0.000 title claims abstract 5
- 108090001012 Transforming Growth Factor beta Proteins 0.000 title claims abstract 5
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title claims abstract 5
- 230000000973 chemotherapeutic effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract 36
- 239000000074 antisense oligonucleotide Substances 0.000 claims abstract 34
- 238000012230 antisense oligonucleotides Methods 0.000 claims abstract 34
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 25
- 239000002246 antineoplastic agent Substances 0.000 claims abstract 10
- 229940127089 cytotoxic agent Drugs 0.000 claims abstract 10
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 claims abstract 8
- 102000011117 Transforming Growth Factor beta2 Human genes 0.000 claims abstract 8
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 claims abstract 8
- 101800000304 Transforming growth factor beta-2 Proteins 0.000 claims abstract 8
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 claims abstract 5
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 claims abstract 5
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims abstract 4
- 201000010099 disease Diseases 0.000 claims abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 3
- 230000001613 neoplastic effect Effects 0.000 claims abstract 3
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims abstract 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims abstract 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims abstract 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims abstract 2
- 230000000692 anti-sense effect Effects 0.000 claims abstract 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims abstract 2
- 229960004316 cisplatin Drugs 0.000 claims abstract 2
- 230000003013 cytotoxicity Effects 0.000 claims abstract 2
- 231100000135 cytotoxicity Toxicity 0.000 claims abstract 2
- 229960003901 dacarbazine Drugs 0.000 claims abstract 2
- 229960003668 docetaxel Drugs 0.000 claims abstract 2
- 229960002949 fluorouracil Drugs 0.000 claims abstract 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims abstract 2
- 229960005277 gemcitabine Drugs 0.000 claims abstract 2
- 229960004768 irinotecan Drugs 0.000 claims abstract 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims abstract 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims abstract 2
- 229960001756 oxaliplatin Drugs 0.000 claims abstract 2
- 229960001603 tamoxifen Drugs 0.000 claims abstract 2
- 229960004964 temozolomide Drugs 0.000 claims abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 8
- 201000009030 Carcinoma Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 206010009944 Colon cancer Diseases 0.000 claims 5
- 201000011066 hemangioma Diseases 0.000 claims 5
- 239000002671 adjuvant Substances 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 239000000314 lubricant Substances 0.000 claims 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 206010003571 Astrocytoma Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000004404 Neurofibroma Diseases 0.000 claims 2
- 208000005890 Neuroma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 208000003362 bronchogenic carcinoma Diseases 0.000 claims 2
- 210000000860 cochlear nerve Anatomy 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000001371 inclusion conjunctivitis Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 206010044325 trachoma Diseases 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 claims 1
- 208000006332 Choriocarcinoma Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000009798 Craniopharyngioma Diseases 0.000 claims 1
- 206010014967 Ependymoma Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010073069 Hepatic cancer Diseases 0.000 claims 1
- 206010025219 Lymphangioma Diseases 0.000 claims 1
- 208000007054 Medullary Carcinoma Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000005927 Myosarcoma Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 201000010133 Oligodendroglioma Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000007641 Pinealoma Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010037649 Pyogenic granuloma Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 206010054184 Small intestine carcinoma Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 208000013938 anaplastic oligoastrocytoma Diseases 0.000 claims 1
- 201000007180 bile duct carcinoma Diseases 0.000 claims 1
- 201000001531 bladder carcinoma Diseases 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 208000019065 cervical carcinoma Diseases 0.000 claims 1
- 201000010989 colorectal carcinoma Diseases 0.000 claims 1
- 208000002445 cystadenocarcinoma Diseases 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 210000004696 endometrium Anatomy 0.000 claims 1
- 208000037828 epithelial carcinoma Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000002250 liver carcinoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 201000005296 lung carcinoma Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 201000002077 muscle cancer Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 claims 1
- 201000010198 papillary carcinoma Diseases 0.000 claims 1
- 208000024724 pineal body neoplasm Diseases 0.000 claims 1
- 201000004123 pineal gland cancer Diseases 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 201000001514 prostate carcinoma Diseases 0.000 claims 1
- 201000010174 renal carcinoma Diseases 0.000 claims 1
- 210000001732 sebaceous gland Anatomy 0.000 claims 1
- 230000002381 testicular Effects 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09166893 | 2009-07-30 | ||
| EP09166893.9 | 2009-07-30 | ||
| PCT/EP2010/061152 WO2011012713A1 (en) | 2009-07-30 | 2010-07-30 | Combination of a chemotherapeutic agent and an inhibitor of the tgf-beta system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012107535A true RU2012107535A (ru) | 2013-09-10 |
Family
ID=41278403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012107535/15A RU2012107535A (ru) | 2009-07-30 | 2010-07-30 | КОМБИНАЦИЯ ХИМИОТЕРАПЕВТИЧЕСКОГО СРЕДСТВА И ИНГИБИТОРА СИСТЕМЫ TGF-β |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8476246B2 (enExample) |
| EP (1) | EP2340308B1 (enExample) |
| JP (1) | JP2013500313A (enExample) |
| KR (1) | KR20120107456A (enExample) |
| CN (1) | CN102712924A (enExample) |
| AU (1) | AU2010277554B2 (enExample) |
| BR (1) | BR112012002102A2 (enExample) |
| CA (1) | CA2769618A1 (enExample) |
| CL (1) | CL2012000247A1 (enExample) |
| CO (1) | CO6511199A2 (enExample) |
| EC (1) | ECSP12011689A (enExample) |
| IL (1) | IL217821A0 (enExample) |
| IN (1) | IN2012DN00969A (enExample) |
| MX (1) | MX2012001244A (enExample) |
| PE (1) | PE20121495A1 (enExample) |
| RU (1) | RU2012107535A (enExample) |
| WO (1) | WO2011012713A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101265180B1 (ko) * | 2002-01-17 | 2013-05-29 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 아이지에프비피-2 및 아이지에프비피-5를 억제하는 양특이성 안티센스 올리고뉴클레오티드, 이를 이용하여 약학적 조성물을 제조하는 방법 및 그 약학적 조성물 |
| US20140031250A1 (en) | 2010-10-07 | 2014-01-30 | David Tsai Ting | Biomarkers of Cancer |
| TWI454281B (zh) * | 2011-10-06 | 2014-10-01 | Nat Univ Tsing Hua | 硼酸於硼中子捕獲治療肝癌之用途 |
| WO2013124869A2 (en) * | 2012-02-21 | 2013-08-29 | Amrita Vishwa Vidyapeetham University | The art, method,manner process and system of fibrous bio-degradable polymeric wafers for the local delivery of therapeutic agents in combinations |
| US20140275214A1 (en) * | 2013-03-14 | 2014-09-18 | Teva Pharmaceutical Industries, Ltd. | Custirsen treatment with reduced toxicity |
| CA2949574C (en) * | 2014-05-23 | 2022-06-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for determining whether a patient will achieve a response after radiation therapy |
| WO2015200697A1 (en) | 2014-06-25 | 2015-12-30 | The General Hospital Corporation | Targeting human satellite ii (hsatii) |
| US11759530B2 (en) * | 2014-11-17 | 2023-09-19 | City Of Hope | TKI permeability enhancers |
| CN108139375A (zh) | 2015-06-26 | 2018-06-08 | 贝斯以色列女执事医疗中心股份有限公司 | 靶向髓样衍生的抑制细胞中的四跨膜蛋白33(tspan33)的癌症疗法 |
| WO2017138924A1 (en) | 2016-02-09 | 2017-08-17 | Autotelic Llc | Compositions and methods for treating pancreatic cancer |
| US9758786B2 (en) | 2016-02-09 | 2017-09-12 | Autotelic, Llc | Compositions and methods for treating pancreatic cancer |
| KR20180103817A (ko) | 2016-02-09 | 2018-09-19 | 오토텔릭 엘엘씨 | 암을 치료하기 위한 조성물과 방법 |
| US11459568B2 (en) | 2016-10-31 | 2022-10-04 | University Of Massachusetts | Targeting microRNA-101-3p in cancer therapy |
| WO2018089688A1 (en) | 2016-11-09 | 2018-05-17 | Jinjun Shi | Restoration of tumor suppression using mrna-based delivery system |
| JP2021512956A (ja) | 2018-02-06 | 2021-05-20 | ザ ジェネラル ホスピタル コーポレイション | 腫瘍免疫応答のバイオマーカーとしてのリピートｒｎａ |
| EP3937980A4 (en) * | 2019-03-14 | 2023-08-02 | The Research Foundation for The State University of New York | Modified micrornas and their use in the treatment of cancer |
| GB201908012D0 (en) * | 2019-06-05 | 2019-07-17 | Io Biotech Aps | TGF-Beta vaccine |
| CN112933238A (zh) * | 2021-02-02 | 2021-06-11 | 石河子大学 | 抑制TGF-βR1基因表达的物质与顺铂在治疗和/或预防食管癌中的应用 |
| CN113425855B (zh) * | 2021-06-28 | 2023-11-07 | 深圳瑞吉生物科技有限公司 | 一种mRNA剂型的骨关节炎药物制剂及其制备方法和应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
| WO1983001451A1 (en) | 1981-10-23 | 1983-04-28 | Molecular Biosystems Inc | Oligonucleotide therapeutic agent and methods of making same |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
| US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
| US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| EP0856579A1 (en) * | 1997-01-31 | 1998-08-05 | BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH | An antisense oligonucleotide preparation method |
| US7795232B1 (en) | 2000-08-25 | 2010-09-14 | Genta Incorporated | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
| US6809118B2 (en) * | 2002-07-25 | 2004-10-26 | Yih-Lin Chung | Methods for therapy of radiation cutaneous syndrome |
| JP4682312B2 (ja) * | 2003-09-04 | 2011-05-11 | 学校法人日本大学 | ＴＧＦ−β遺伝子発現抑制剤 |
| KR20060127409A (ko) * | 2003-11-13 | 2006-12-12 | 제넨테크, 인크. | 종양 치료 방법 및 스크리닝 검정 |
| ZA200602941B (en) * | 2003-11-13 | 2007-07-25 | Genentech Inc | Screening assays and methods of tumor treatment |
| CA2550058C (en) * | 2003-12-19 | 2016-07-12 | Antisense Pharma Gmbh | Pharmaceutical composition comprising a tgf-beta2 antisense oligonucleotide and a chemotherapeutic |
| CA2558667A1 (en) * | 2004-02-27 | 2005-09-15 | Antisense Pharma Gmbh | Antisense oligonucleotides for inhibiting the formation of metastases in cancer |
| US20090186076A1 (en) * | 2006-02-01 | 2009-07-23 | Kazunori Kataoka | Combined Use of TGF-Beta Signaling Inhibitor and Antitumor Agent |
| JP5322476B2 (ja) * | 2008-03-31 | 2013-10-23 | テルモ株式会社 | リポソームの製造装置およびリポソームの製造方法 |
-
2010
- 2010-07-30 PE PE2012000130A patent/PE20121495A1/es not_active Application Discontinuation
- 2010-07-30 IN IN969DEN2012 patent/IN2012DN00969A/en unknown
- 2010-07-30 RU RU2012107535/15A patent/RU2012107535A/ru not_active Application Discontinuation
- 2010-07-30 KR KR1020127005337A patent/KR20120107456A/ko not_active Withdrawn
- 2010-07-30 US US13/059,623 patent/US8476246B2/en active Active
- 2010-07-30 MX MX2012001244A patent/MX2012001244A/es active IP Right Grant
- 2010-07-30 CA CA2769618A patent/CA2769618A1/en not_active Abandoned
- 2010-07-30 BR BR112012002102A patent/BR112012002102A2/pt not_active IP Right Cessation
- 2010-07-30 AU AU2010277554A patent/AU2010277554B2/en not_active Ceased
- 2010-07-30 EP EP10737580.0A patent/EP2340308B1/en not_active Not-in-force
- 2010-07-30 JP JP2012522185A patent/JP2013500313A/ja active Pending
- 2010-07-30 CN CN2010800436805A patent/CN102712924A/zh active Pending
- 2010-07-30 WO PCT/EP2010/061152 patent/WO2011012713A1/en not_active Ceased
-
2012
- 2012-01-29 IL IL217821A patent/IL217821A0/en unknown
- 2012-01-30 CL CL2012000247A patent/CL2012000247A1/es unknown
- 2012-02-23 EC ECSP12011689 patent/ECSP12011689A/es unknown
- 2012-02-29 CO CO12035227A patent/CO6511199A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2340308A1 (en) | 2011-07-06 |
| WO2011012713A1 (en) | 2011-02-03 |
| US20120027873A1 (en) | 2012-02-02 |
| JP2013500313A (ja) | 2013-01-07 |
| CL2012000247A1 (es) | 2013-07-05 |
| IL217821A0 (en) | 2012-03-29 |
| US8476246B2 (en) | 2013-07-02 |
| CA2769618A1 (en) | 2011-02-03 |
| BR112012002102A2 (pt) | 2017-05-02 |
| AU2010277554B2 (en) | 2015-02-19 |
| CO6511199A2 (es) | 2012-08-31 |
| CN102712924A (zh) | 2012-10-03 |
| IN2012DN00969A (enExample) | 2015-04-10 |
| EP2340308B1 (en) | 2014-12-24 |
| MX2012001244A (es) | 2012-03-26 |
| AU2010277554A1 (en) | 2012-03-01 |
| PE20121495A1 (es) | 2012-11-19 |
| KR20120107456A (ko) | 2012-10-02 |
| ECSP12011689A (es) | 2012-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012107535A (ru) | КОМБИНАЦИЯ ХИМИОТЕРАПЕВТИЧЕСКОГО СРЕДСТВА И ИНГИБИТОРА СИСТЕМЫ TGF-β | |
| Piso et al. | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer | |
| RU2014108042A (ru) | Фармацевтическая композиция для лечения и профилактики злокачественной опухоли | |
| Hegde et al. | Systemic and targeted therapy for advanced colon cancer | |
| JP2008506683A5 (enExample) | ||
| RU2014108049A (ru) | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли | |
| RU2018100142A (ru) | Гетероциклические соединения, эффективные для ингибирования киназы | |
| RU2014108045A (ru) | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли | |
| RU2014108043A (ru) | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли | |
| JP2017530171A5 (enExample) | ||
| Yu et al. | Anticancer activity of a series of platinum complexes integrating demethylcantharidin with isomers of 1, 2-diaminocyclohexane | |
| Phelip et al. | High resectability rate of initially unresectable colorectal liver metastases after UGT1A1-adapted high-dose irinotecan combined with LV5FU2 and cetuximab: A multicenter phase II study (ERBIFORT) | |
| CN111818925A (zh) | Cdk4/6抑制剂与egfr抑制剂联合在制备治疗肿瘤疾病的药物中的用途 | |
| Sommariva et al. | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal sarcomatosis: long-term outcome from a single institution experience | |
| Glehen et al. | New perspectives in the management of colorectal cancer: what about peritoneal carcinomatosis? | |
| ATE540674T1 (de) | Verwendung einer antikrebsverbindung | |
| Huo et al. | Discovery of pyrimidine-bridged CA-4 CBSIs for the treatment of cervical cancer in combination with cisplatin with significantly reduced nephrotoxicity | |
| Nishikawa et al. | Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study. | |
| Feng et al. | Case report: Aumolertinib as neoadjuvant therapy for patients with unresectable stage III non-small cell lung cancer with activated EGFR mutation: Case series | |
| Bahrami et al. | Clonal relationships between epidermotropic metastatic melanomas and their primary lesions: a loss of heterozygosity and X-chromosome inactivation-based analysis | |
| Koo et al. | A Phase II Study of Cetuximab (Erbitux®) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer | |
| JPWO2023008462A5 (enExample) | ||
| Collins et al. | Gastrointestinal perforation in metastatic carcinoma: a complication of bevacizumab therapy | |
| Götze et al. | Preoperative Chemotherapy | |
| JP2008533161A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20160210 |